Filing Summary
Registrant: Vallon Pharmaceuticals, Inc. (the request metadata identifies GRI Bio, Inc.; the filing itself names Vallon Pharmaceuticals, Inc.)
Filing type and date: Form 8-K filed March 21, 2022, under Item 8.01 (Other Events). This is not a periodic financial report and does not provide financial statements or a defined reporting period.
Business Context
The filing announces that Vallon issued a press release reporting top-line results from its pivotal SEAL study of ADAIR, the company’s proprietary abuse-deterrent formulation of immediate-release dextroamphetamine for attention deficit hyperactivity disorder.
Financial and Operating Metrics
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
- The filing text provided does not include the reported SEAL study results or specific clinical-performance metrics; those details were contained in Exhibit 99.1, the referenced press release, which is not included in the supplied text.
Material Changes and Outlook
- The reported event is the release of top-line results from the pivotal SEAL study.
- No guidance, forecasts, management outlook, risk updates, contingencies, financing plans, or unusual financial items are provided in the filing text.
Important Facts to Verify
- Obtain and review Exhibit 99.1 to verify the actual SEAL study results, statistical significance, endpoints, safety findings, and management’s interpretation.
- Confirm the registrant identity because the supplied metadata names GRI Bio, Inc., while the filing names Vallon Pharmaceuticals, Inc. and reports trading symbol VLON.
- Review subsequent filings for regulatory plans, additional clinical data, financing needs, and the potential impact of the study results on ADAIR’s development program.